Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. Antibody–drug conjugates for cancer: poised to deliver?. Nat Rev Drug Discov 9, 665–667 (2010). https://doi.org/10.1038/nrd3270
Issue Date:
DOI: https://doi.org/10.1038/nrd3270